This phenomenon is highlighted in a phase III clinical trial within a cohort of 369 patients with recurrent glioblastoma, where immunotherapeutics like Nivolumab—an IgG4 monoclonal antibody that blocks the PD-1 receptor—did not prove to be superior to other treatments, such as Bevacizumab (an inhibitor of the VEGF angiogenic factor) [45]. The gene discussed is VEGFA; the disease is glioblastoma.